At ASCO 2026, Revolution Medicines delivered detailed Phase 3 data for daraxonrasib, a pan-RAS inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma. The report follows earlier top-line disclosures and was published in parallel in the New England Journal of Medicine. The Phase 3 RASolute 302 program reported a strong overall survival outcome, including benefit across KRAS-mutant and broader populations, moving the discussion beyond early efficacy signals toward durability and clinical relevance against a difficult historical backdrop. Separately, the meeting also featured ongoing competition in precision oncology combinations, reinforcing that RAS-pathway targeting remains a high-stakes area for both scientific validation and future trial strategy. Together, the ASCO disclosures shift attention to how daraxonrasib will be positioned for subsequent studies, sequencing, and potential regulatory engagement.